Alejandro M. L.
- Country
- Spain
- Department
- Dermatology
Research Overview
- Efficacy and Safety Evaluation of Tulisokibart in Moderate to Severe Hidradenitis Suppurativa: A Phase 2b Randomized, Double-Blind, Placebo-Controlled Trial
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Ritlecitinib in Adults with Moderate to Severe Hidradenitis Suppurativa
- A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients with Moderate to Severe Hidradenitis Suppurativa
Data & Insights
Has run more than one trial at 183 of 346 partner sites.
Specializations
Inflammatory Skin Conditions
The investigator specializes in the treatment and research of hidradenitis suppurativa, a chronic inflammatory skin condition that affects hair follicles in areas where skin rubs together.
- Moderate to severe disease manifestations
- Treatment-resistant cases
- Complex inflammatory patterns
Their work encompasses evaluation of novel therapeutic approaches for patients who have failed conventional treatments.
Advanced Therapeutics
The investigator focuses on evaluating innovative treatment modalities including biological therapies and small molecule inhibitors for inflammatory skin conditions.
- Novel biological agents
- JAK inhibitors
- Cell-based therapies
Their research includes assessment of both systemic and targeted therapeutic approaches.
Clinical Outcomes
The investigator evaluates therapeutic efficacy through long-term disease management and assessment of clinical responses in chronic inflammatory conditions.
- Treatment response markers
- Safety profiling
- Disease progression monitoring
Their work includes evaluation of clinical endpoints and patient response patterns to various therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.